Skip to content

Variant II Turbo Link Hemoglobin A1C Program, and Variant II Turbo Link Hemoglobin Testing with Model, 270-2716,

by Bio-Rad Laboratories Inc., Clinical Systems Divisi 510(k)

Active United States

510(k) K070819

Regulatory status

as of 28 Oct 2026

RegionAuthorizationNumberDateStatus
United StatesFDA 510(k)SESE Substantially Equivalent · Traditional NumberK070819 Date25 Jun 2007ClearedStatusActive

Coverage

1 jurisdiction

United States of America
  • Active
  • Expiring
  • Withdrawn
  • Listed
  • Not covered

United States — FDA 510(k) Active

Recalls

5 recalls · FDA

    • Terminated Z-0399-2012 FDA Unclassified (pre-2012) initiated 25 Oct 2011 on shared 510(k) K070819

    It was discovered that the Variant II Turbo Link Calibrator Values card contains incorrect values for IFCC units. The numbers are missing a decimal point.

  • 2 recalls, same reason

    • Terminated Z-0027-2012 FDA Unclassified (pre-2012) initiated 12 Sep 2011
    • Terminated Z-0026-2012 FDA Unclassified (pre-2012) initiated 12 Sep 2011

    A previous recall related to reports of calibration failure and late retention times using Elution Buffer led to an examination of other buffers manufactured during the same time period and a decision was made to field correct these products until a definitive root cause and corrective action have been found and implemented.

    • Terminated Z-3159-2011 FDA Unclassified (pre-2012) initiated 28 Jul 2011

    The Elution Buffer B, lot no. GA 10430, was shipped in a 2.0 L bottle instead of the standard 2.5 L bottle.

    • Terminated Z-1259-2011 FDA Unclassified (pre-2012) initiated 19 Feb 2010

    The results from the blood device had the occurrence of some ramping baselines on their chromatograms. The ramping baseline can affect quantitation of the blood results.

Recalls on a shared submission name another device cleared under the same FDA submission as this one.

Specification

510(k)

510(k) Number
FDA Product Code
LCP
Device Class
Class II
Regulation
21 CFR Part 864.7470
Advisory Committee
Hematology
FDA Decision
SESE Substantially Equivalent

Other devices from Bio-Rad Laboratories, Inc., Clinical Systems Divis